2 assets in Central Sleep Apnea Syndrome

Therapeutic assets addressing Central Sleep Apnea Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Acetazolamide Central Sleep Apnea Syndrome	University of California, San Diego	P2	B (56)
ACETIC Central Sleep Apnea Syndrome	Ottawa Heart Institute Research Corporation	N/A	D (30)